Literature DB >> 27649787

Therapy: Gastrointestinal safety of incretin therapies: are we there yet?

Juris J Meier1, Julio Rosenstock2.   

Abstract

Year:  2016        PMID： 27649787     DOI： 10.1038/nrgastro.2016.149

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  10 in total

Review 1.  Smoke or fire? Acute pancreatitis and the liraglutide trials.

Authors:  Edwin A M Gale
Journal:  Diabetes Care       Date:  2015-06       Impact factor: 19.112

2.  Cardiovascular and non-cardiovascular safety of dipeptidyl peptidase-4 inhibition: a meta-analysis of randomized controlled cardiovascular outcome trials.

Authors:  A S Abbas; H-M Dehbi; K K Ray
Journal:  Diabetes Obes Metab       Date:  2015-12-23       Impact factor: 6.577

Review 3.  Incretin-based drugs and adverse pancreatic events: almost a decade later and uncertainty remains.

Authors:  Laurent Azoulay
Journal:  Diabetes Care       Date:  2015-06       Impact factor: 19.112

4.  Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.

Authors:  Melanie J Davies; Richard Bergenstal; Bruce Bode; Robert F Kushner; Andrew Lewin; Trine Vang Skjøth; Arne Haahr Andreasen; Christine Bjørn Jensen; Ralph A DeFronzo
Journal:  JAMA       Date:  2015-08-18       Impact factor: 56.272

5.  Risk of pancreatitis in patients treated with incretin-based therapies.

Authors:  Juris J Meier; Michael A Nauck
Journal:  Diabetologia       Date:  2014-04-11       Impact factor: 10.122

6.  Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial.

Authors:  Julio Rosenstock; Michaela Diamant; Vanita R Aroda; Louise Silvestre; Elisabeth Souhami; Tianyue Zhou; Riccardo Perfetti; Vivian Fonseca
Journal:  Diabetes Care       Date:  2016-06-09       Impact factor: 19.112

Review 7.  GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.

Authors:  Juris J Meier
Journal:  Nat Rev Endocrinol       Date:  2012-09-04       Impact factor: 43.330

8.  Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis.

Authors:  Laurent Azoulay; Kristian B Filion; Robert W Platt; Matthew Dahl; Colin R Dormuth; Kristin K Clemens; Madeleine Durand; Nianping Hu; David N Juurlink; J Michael Paterson; Laura E Targownik; Tanvir C Turin; Pierre Ernst; Samy Suissa; Colin R Dormuth; Brenda R Hemmelgarn; Gary F Teare; Patricia Caetano; Dan Chateau; David A Henry; J Michael Paterson; Jacques LeLorier; Adrian R Levy; Pierre Ernst; Robert W Platt; Ingrid S Sketris
Journal:  JAMA Intern Med       Date:  2016-10-01       Impact factor: 21.873

9.  Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus.

Authors:  Jean-Luc Faillie; Oriana H Yu; Hui Yin; Dominique Hillaire-Buys; Alan Barkun; Laurent Azoulay
Journal:  JAMA Intern Med       Date:  2016-10-01       Impact factor: 21.873

10.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse
Journal:  N Engl J Med       Date:  2016-06-13       Impact factor: 176.079
  10 in total
  2 in total

1.  Incretin-based therapy and pancreatitis: accumulating evidence and unresolved questions.

Authors:  Yoshifumi Saisho
Journal:  Ann Transl Med       Date:  2018-04

2.  Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.

Authors:  Melanie Davies; Thomas R Pieber; Marie-Louise Hartoft-Nielsen; Oluf K H Hansen; Serge Jabbour; Julio Rosenstock
Journal:  JAMA       Date:  2017-10-17       Impact factor: 56.272
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.